Stereotaxis

Stereotaxis AAQS

The The AAQS of Stereotaxis (STXS) as of Nov 18, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

Stereotaxis has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Stereotaxis in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Stereotaxis AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
3.00 USD
Jan 1, 2019
3.00 USD
Jan 1, 2020
3.00 USD
Jan 1, 2021
3.00 USD
Jan 1, 2022
3.00 USD
Jan 1, 2023
3.00 USD
Jan 1, 2024
3.00 USD
Jan 1, 2025
3.00 USD
The Stereotaxis AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stereotaxis Stock analysis

What does Stereotaxis do? Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future. Stereotaxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stereotaxis stock

The AAQS of Stereotaxis is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Stereotaxis since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Stereotaxis

All Key Metrics — Stereotaxis